Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

31.28 +0.11 (+0.35%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Top Stocks That Just Increased Their Dividends
There are several reasons why investors tend to favor stocks that have had a dividend increase. 
Via Talk Markets
Royalty Pharma Announces Dividend Increase
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX appears to be flying under the radar despite its strong fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX is an undervalued gem with solid fundamentals.
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
NASDAQ:RPRX: good value for what you're paying.
Despite its impressive fundamentals, ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) remains undervalued. 
Via Chartmill
Royalty Pharma's Earnings Outlook
Via Benzinga
Earnings Scheduled For February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. 
Via Benzinga
Royalty Pharma's Earnings: A Preview
Via Benzinga
3 Biotech Stocks to Buy for the Next Bull Run: February 2024
These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month. 
Via InvestorPlace
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals. 
Via Chartmill
How Risky Is Royalty Pharma’s Dividend?
Royalty Pharma just announced a 5% dividend increase, its fourth raise in a row. It has boosted the dividend every year since it began paying one in 2020. The new $0.21 per share quarterly dividend... 
Via Talk Markets
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Royalty Pharma Reports Third Quarter 2023 Results
From Royalty Pharma plc
Via GlobeNewswire
Why PTC Therapeutics Soared 15% Higher Today
The company scored a $1 billion upfront payment for expanding a commercial partnership. 
Via The Motley Fool
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Declares Fourth Quarter 2023 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Eric Schneider as Chief Technology Officer
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)
From Royalty Pharma plc
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 169 companies set new 52-week lows. 
Via Benzinga
Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg)
From Ferring Pharmaceuticals
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS